Universal nanosponge for treating respiratory viral infection
A nanoparticle comprising an outer surface comprising a plasma membrane derived from a cell that can be infected with a respiratory virus, including a human lung epithelial cell expressing ACE-2 receptor. Methods of manufacture and use for preventing or treating viral infections, such as coronavirus infection in a subject in need are disclosed.
1. A nanoparticle comprising an outer surface comprising a plasma membrane derived from a human lung epithelial cell or macrophage that can be infected with a respiratory virus.
2. The nanoparticle of claim 1 , further comprising an inner core comprising a non-cellular material.
3. The nanoparticle of claim 1 , wherein the plasma membrane is derived from the human lung epithelial cell.
4. The nanoparticle of claim 1 , wherein the plasma membrane comprises angiotensin-converting enzyme 2 (ACE-2) receptors.
5. The nanoparticle of claim 1 , wherein the nanoparticle further comprises a releasable cargo.
6. The nanoparticle of claim 5 , wherein the releasable cargo is a therapeutic agent, a prophylactic agent, a diagnostic or marker agent, a prognostic agent, or a combination thereof.
7. The nanoparticle of claim 1 , wherein the respiratory virus is a coronavirus.
8. The nanoparticle of claim 7 , wherein the coronavirus is SARS-CoV-2.
9. A medicament delivery system, which comprises an effective amount of the nanoparticle of claim 1 .
10. A pharmaceutical composition comprising an effective amount of the nanoparticle of claim 1 and a pharmaceutically acceptable carrier or excipient.
11. A method for treating a disease or condition in a subject in need thereof comprising administering to said subject an effective amount of the nanoparticle of claim 1 , wherein the disease or condition is a coronavirus infection.
12. A process for making a nanoparticle comprising:
a) combining an inner core comprising a non-cellular material, and an outer surface comprising a membrane derived from a human lung epithelial cell or macrophage that can be infected with a respiratory virus; and
b) exerting exogenous energy on the combination to form a nanoparticle comprising said inner core and said outer surface.
13. The process for making a nanoparticle of claim 12 , wherein the respiratory virus is a coronavirus.
14. The process for making a nanoparticle of claim 12 , wherein the membrane derived from a cell is genetically modified.
15. A coronavirus-specific composition comprising an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising an outer membrane vesicle derived from a human lung epithelial cell or macrophage that can be infected with a coronavirus.
16. A method for treating a coronavirus infection in a human subject in need thereof comprising administering to said subject an effective amount of the coronavirus-specific composition of claim 15 .
17. The method of claim 16 , wherein the nanoparticle is administered via an oral, nasal, inhalational, parenteral, intravenous, intraperitoneal, subcutaneous, intramuscular, intradermal, topical, or rectal route.
18. The method of claim 16 , wherein the nanoparticle substantially maintains natural structural integrity or activity of the cellular membrane or the constituents of the cellular membrane.
19. The method of claim 18 , wherein the coronavirus is SARS-CoV-2.
20. The nanoparticle of claim 1 , wherein the plasma membrane does not comprise any portion of the respiratory virus.